Quick trip? LSD plus risperidone tested for depression
NCT ID NCT07503002
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 3 times
Summary
This early-phase study tests whether a shortened LSD experience, combined with the drug risperidone, can safely ease symptoms of major depression. Ten adults with moderate to severe depression will receive LSD followed by risperidone 45 minutes later. Researchers will monitor safety and measure changes in depression scores over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Johns Hopkins Center for Psychedelic and Consciousness Research
Baltimore, Maryland, 21224, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain wave clues: could inflammation markers forecast ECT outcomes?
- Brain scans may guide psychedelics and magnetic pulses to quell suicidal thoughts
- Brain wave patterns and inflammation: a clue to ECT's effectiveness in older adults?
- A headset for depression in pregnancy — science tests a Drug-Free option
- Can a common supplement lift depression and sharpen memory in seniors?
- Can pulling an all-nighter reveal how depression hijacks sleep and mood?